Lakefront Biotherapeutics (LKFT) Equity Average (2015)
Lakefront Biotherapeutics (LKFT) reported Equity Average of $328.9 million for Q4 2015.
Lakefront Biotherapeutics (LKFT) Equity Average (2015) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 1 years of Equity Average data on file, last reported at $328.9 million in Q4 2015.
- Equity Average for Q4 2015 came in at $328.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2015 was $328.9 million (changed N/A YoY), and the FY2025 annual result was $3.4 billion, up 12.43% from the prior year.
- Equity Average was little changed at $328.9 million in Q4 2015 per LKFT's latest filing.
- Over five years, Equity Average peaked at $328.9 million in Q4 2015 and troughed at $328.9 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 516.41 Mn |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 328.86 Mn |